Phio Pharmaceuticals Corp. 8-K

What Happened
Phio Pharmaceuticals Corp. (PHIO) announced on March 30, 2026 (filed via Form 8-K, Item 8.01) that it has entered into a cGMP drug product manufacturing services agreement with a U.S.-based manufacturer to produce clinical supply. The company issued a press release about the agreement, which is attached to the filing as Exhibit 99.1 and incorporated by reference.

Key Details

• Filing: Form 8-K, Item 8.01 – Other Events, dated March 30, 2026.
• Agreement type: cGMP drug product manufacturing services agreement for clinical supply.
• Counterparty: described as a U.S. manufacturer (no company name disclosed in the 8-K).
• Press release: full text attached as Exhibit 99.1 to the 8-K.

Why It Matters
Securing a cGMP manufacturing services agreement is an operational step that provides for production of clinical‑grade drug product, addressing a key logistical need for a clinical‑stage biopharma. The filing does not disclose financial terms, timetable, or the manufacturer’s identity, so investors should view this as confirmation that Phio has arranged clinical supply but not as an update on costs, trial timing, or commercial manufacturing plans.